Compare Annaly Capital Management, Inc. (NLY) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs Viatris Inc — how do they compare? Annaly Capital Management, Inc. trades at $22.89 (market cap $16.63B), while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: Viatris Inc is the larger of the two by market cap, and Annaly Capital Management, Inc. pays the higher dividend (13.22%). Which is the better fit depends on your goals.
| NLY | VTRS | |
|---|---|---|
Market Cap | $16.63B | $19.79B |
Sector | Financials | Health |
52-Week High | $24.40 | $17.39 |
52-Week Low | $19.96 | $8.74 |
Dividend Yield | 13.22% | 2.83% |
Enterprise Value | — | $32.00B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
